San Diego’s Fate Therapeutics has raised $10.3 million in an equity deal, according to a recent form filed with the Securities and Exchange Commission.

According to the SEC, the Form D was submitted Aug. 19 and the financing included four investors.

Fate Therapeutics, a thinly-traded public company with a market cap of $82.6 million, is developing programmed cellular therapeutics for the treatment of severe, life-threatening disease.

The company’s executive staff went through a recent shuffling, with Dr. Christian Weyer stepping down as president and CEO last year. The company’s former CFO, Scott Wolchko, stepped into the roles in October. Fate also recently brought on Dr. Chris Storgard, former clinical head of Ardea Biosciences, as chief medical officer.